Front Page
Critical Limb Ischemia
 |
Critical Limb Ischemia |
| Affecting over 30 million patients worldwide, Critical Limb Ischemia (CLI) is a growing unmet need that results in over 40,000 amputations in the US alone each year. Existing interventions lack durability, requiring a repeat intervention as soon as 3 months later in the majority of CLI patients. There is no FDA approved technology to improve procedure durability below-the-knee. SoundPipe is developing a novel, intravascular ultrasound platform to address this unmet need. |
Penello
Our Platform
The Penello platform is an intravascular ultrasound system that uses a catheter mounted ultrasound device to improve drug delivery. This will allow interventionalists to deliver antiproliferative drugs to the diseased vessel safely. Currently under development, our patented technology will revolutionize the treatment of CLI.
 |
Feedback
What are doctors telling us about Penello?
As part of the ICorps@NIH, our team interviewed over 55 doctors to understand how Penello could best help their patients. Here is some of the feedback we received.
“I think you have something very exciting that may help our field and patients”
“That would be amazing!”
“Unbridled enthusiasm.”
“New approaches to interventions such as this could have some societal benefits as well.”
About
About SoundPipe
Founded in 2013, SoundPipe’s team has grown to include experts in medicine, business, and engineering. We are committed to bringing sound solutions through sound science.
Leadership
 |
Joe Kilroy, PhD (Chief Executive Officer, Co-Founder, Board Member): An expert in intravascular ultrasound and microbubble-based drug delivery. Since co-founding SoundPipe, Joe has continued development of Penello, coordinated the regulatory strategy formation, managed SoundPipe’s intellectual property, and secured four Small Business Innovation Research grants. | |
Board of Directors
 |
Jonathan Sackier, M.B.ChB (Non-Executive Chairman) : A surgeon and serial entrepreneur with multiple commercial successes. Jonathan has participated in the development of breakthrough medical technologies including laparoscopic surgery, amniotic stem cells, and the first commercial surgical robot (AESOP). He has served as a director and board member for multiple biotechnology startups | |
 |
Gary Henry (Board Member): A successful serial founder, principal, and angel investor. Gary’s career includes 26 years with GE during which he started two businesses, one in Europe and one in the United States. Since then he has been a CEO and COO for startup and growth companies and founder and Executive Director of the Charlottesville Technology Incubator. | |
 |
Paul Magnin, PhD (Board Member): A serial entrepreneur and advisor. Paul has over 35 years experience in the medical ultrasound field. After 17 years as a key contributor to Hewlett-Packard’s Imaging Systems business, Paul was the CEO of two intravascular imaging device companies, LightLab Imaging and Novelis, that were sold to Goodman Ltd and Volcano Corporation | |
Advisory Board
 |
John Hossack, PhD (Scientific Advisor, Co-Founder): A UVA professor and leader in the field of ultrasound imaging and microbubble-based drug delivery. John has over 28 years experience developing ultrasound technologies including as a Fellow at Acuson and as a co-founder of PocketSonics, which was sold to Analogics in 2013. | |
 |
Brian Wamhoff, PhD (Scientific Advisor, Co-Founder): A serial biotechnology entrepreneur and former UVA professor. Brian is co-founder of HemoShear Therapeutics, where he has secured NIH SBIR funding and industry partnerships as Head of R&D. Brian is a former inventor at Setagon, a drug-eluting stent developer with a successful exit. | |
 |
William Mac Thompson Jr., J.D. (Legal Counsel): Mac Thompson practices business and corporate law representing companies in diverse fields including biotechnology, high-tech, education, energy, and manufacturing. Mac serves on the boards of many privately held companies and has been active in numerous nonprofit organizations in Charlottesville. | |